| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $21.2M | +50.1% |
| SG&A Expense | $16.0M | +18.2% |
| Operating Income | -$37.1M | -34.5% |
| Pre-tax Income | -$34.8M | -36.3% |
| Income Tax | $0 | — |
| Net Income | -$34.8M | -36.3% |
| EPS (Basic) | -$4.04 | -1920.0% |
| EPS (Diluted) | -$4.04 | -1920.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $41.3M | -41.9% |
| Current Assets | $45.6M | -38.7% |
| Total Assets | $47.6M | -37.7% |
| Current Liabilities | $8.3M | +66.2% |
| Total Liabilities | $8.3M | +66.2% |
| Stockholders' Equity | $39.4M | -44.9% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$29.8M | -41.5% |
| Capital Expenditures | $23K | +21.1% |
| Investing Cash Flow | -$23K | -21.1% |
| Financing Cash Flow | $0 | -100.0% |
| Free Cash Flow | -$29.8M | -41.5% |